

Applicants: Graham P. Allaway et al.

Serial No.: 09/904,356

Filed: July 12, 2001

Page 2 of 5 of Amendment In Response To December 10, 2009 Office Action

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-25. (Canceled)

26. (Currently amended) A method of ~~specifically~~ inhibiting fusion of an HIV-1 envelope glycoprotein^{[[+]]}₊ cell with a CD4^{[[+]]}₊ cell that fuses with such HIV-1 envelope glycoprotein^{[[+]]}₊ cell, which comprises contacting the CD4^{[[+]]}₊ cell with an anti-PM1 monoclonal antibody that (1) significantly inhibits macrophage-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{JR-FL} ~~to~~ with a CD4⁺ PM1 cell, ~~but~~ and (2) does not significantly inhibit T cell-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{LAI} ~~to~~ with a HeLa-CD4^{[[+]]}₊ cell, so as to thereby inhibit fusion of the HIV-1 envelope glycoprotein^{[[+]]}₊ cell with the CD4⁺ cell.

27. (Canceled)

28. (Previously presented) The method of claim 26, wherein the anti-PM1 monoclonal antibody is a chimeric antibody.

29. (Previously presented) The method of claim 26, wherein the anti-PM1 monoclonal antibody is a synthetic antibody.

30. (Previously presented) The method of claim 26, wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.

31-35. (Canceled)